Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Bio-Techne Corporation (TECH)

NMS · Biotechnology

$72.07+0.45 (+0.63%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$11.23B
P/E (TTM)
101.51
EPS
$0.71
Div Yield
0.45%
52W Range
$43.20–$72.16
Beta
1.29

Company overview

Next earnings: 2026-08-05(8d)

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Peers in Biotechnology

All in industry →

Recent press releases

Bio-Techne Corporation has not issued a press release in this window.

SEC filings

All filings →

Bio-Techne Corporation has not filed an SEC document in this window.

Bio-Techne Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
6,566 sh-99.6%
1,649,129 sh● NEW
8,345,414 sh+15.3%
2,364,845 sh+157.8%
1,207,499 sh-51.6%
3,850,923 sh+27.8%

People at Bio-Techne Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
12/24
$27.4M
NI $34.9M
03/25
$316.2M
NI $22.6M
09/25
$286.6M
NI $38.2M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.24
Prior: $0.14
Revenue sparkline